ARCTURUS THERAPEUTICS HOLDIN (ARCT) Stock Fundamental Analysis
USA - NASDAQ:ARCT - US03969T1097 - Common Stock
8.13 USD
-0.54 (-6.23%)
8.06 USD
-0.07 (-0.86%)
We assign a fundamental rating of 4 out of 10 to ARCT. ARCT was compared to 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ARCT as it has an excellent financial health rating, but there are worries on the profitability. ARCT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ARCT has reported negative net income.
ARCT had a negative operating cash flow in the past year.
ARCT had negative earnings in 4 of the past 5 years.
In the past 5 years ARCT reported 4 times negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -19.45%, ARCT is doing good in the industry, outperforming 76.08% of the companies in the same industry.
Looking at the Return On Equity, with a value of -26.04%, ARCT is in the better half of the industry, outperforming 79.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.45% | ||
| ROE | -26.04% | ||
| ROIC | N/A |
ROA(3y)-9.46%
ROA(5y)-19.07%
ROE(3y)-13.61%
ROE(5y)-29.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ARCT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ARCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARCT has been increased compared to 1 year ago.
Compared to 5 years ago, ARCT has more shares outstanding
There is no outstanding debt for ARCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of 0.17, we must say that ARCT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ARCT (0.17) is better than 61.21% of its industry peers.
ARCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.17 |
ROIC/WACCN/A
WACC8.77%
2.3 Liquidity
ARCT has a Current Ratio of 5.90. This indicates that ARCT is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.90, ARCT is doing good in the industry, outperforming 62.90% of the companies in the same industry.
A Quick Ratio of 5.90 indicates that ARCT has no problem at all paying its short term obligations.
ARCT's Quick ratio of 5.90 is fine compared to the rest of the industry. ARCT outperforms 63.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.9 | ||
| Quick Ratio | 5.9 |
3. Growth
3.1 Past
ARCT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.81%.
The Revenue has decreased by -8.69% in the past year.
Measured over the past years, ARCT shows a very strong growth in Revenue. The Revenue has been growing by 48.91% on average per year.
EPS 1Y (TTM)-10.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.46%
Revenue 1Y (TTM)-8.69%
Revenue growth 3Y130.73%
Revenue growth 5Y48.91%
Sales Q2Q%-58.85%
3.2 Future
Based on estimates for the next years, ARCT will show a very strong growth in Earnings Per Share. The EPS will grow by 31.96% on average per year.
Based on estimates for the next years, ARCT will show a very strong growth in Revenue. The Revenue will grow by 21.93% on average per year.
EPS Next Y10.59%
EPS Next 2Y-9.68%
EPS Next 3Y10.46%
EPS Next 5Y31.96%
Revenue Next Year-45.85%
Revenue Next 2Y-17.13%
Revenue Next 3Y2.25%
Revenue Next 5Y21.93%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ARCT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.68%
EPS Next 3Y10.46%
5. Dividend
5.1 Amount
No dividends for ARCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
8.13
-0.54 (-6.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners89.49%
Inst Owner Change0.73%
Ins Owners0.82%
Ins Owner Change0%
Market Cap220.73M
Revenue(TTM)152.31M
Net Income(TTM)-60.16M
Analysts81.18
Price Target45.67 (461.75%)
Short Float %21.22%
Short Ratio4.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)62.16%
Min EPS beat(2)61.7%
Max EPS beat(2)62.62%
EPS beat(4)3
Avg EPS beat(4)26.29%
Min EPS beat(4)-98.22%
Max EPS beat(4)79.04%
EPS beat(8)7
Avg EPS beat(8)39.56%
EPS beat(12)10
Avg EPS beat(12)236.3%
EPS beat(16)12
Avg EPS beat(16)178.2%
Revenue beat(2)2
Avg Revenue beat(2)15.02%
Min Revenue beat(2)9.67%
Max Revenue beat(2)20.36%
Revenue beat(4)3
Avg Revenue beat(4)-2.09%
Min Revenue beat(4)-50.01%
Max Revenue beat(4)20.36%
Revenue beat(8)6
Avg Revenue beat(8)49.54%
Revenue beat(12)9
Avg Revenue beat(12)68.63%
Revenue beat(16)10
Avg Revenue beat(16)114.11%
PT rev (1m)-30.87%
PT rev (3m)-24.57%
EPS NQ rev (1m)-18.87%
EPS NQ rev (3m)10.12%
EPS NY rev (1m)-8.92%
EPS NY rev (3m)17.86%
Revenue NQ rev (1m)-8.55%
Revenue NQ rev (3m)2%
Revenue NY rev (1m)-5.68%
Revenue NY rev (3m)3.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.81 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.96 | ||
| P/tB | 0.96 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.46
EYN/A
EPS(NY)-3.62
Fwd EYN/A
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.39
OCFYN/A
SpS4.5
BVpS8.51
TBVpS8.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.45% | ||
| ROE | -26.04% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-9.46%
ROA(5y)-19.07%
ROE(3y)-13.61%
ROE(5y)-29.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 6.55% | ||
| Cap/Sales | 0.18% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.9 | ||
| Quick Ratio | 5.9 | ||
| Altman-Z | 0.17 |
F-Score2
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)207.21%
Cap/Depr(5y)221.18%
Cap/Sales(3y)1.97%
Cap/Sales(5y)10.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.46%
EPS Next Y10.59%
EPS Next 2Y-9.68%
EPS Next 3Y10.46%
EPS Next 5Y31.96%
Revenue 1Y (TTM)-8.69%
Revenue growth 3Y130.73%
Revenue growth 5Y48.91%
Sales Q2Q%-58.85%
Revenue Next Year-45.85%
Revenue Next 2Y-17.13%
Revenue Next 3Y2.25%
Revenue Next 5Y21.93%
EBIT growth 1Y18.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.43%
EBIT Next 3Y1.16%
EBIT Next 5YN/A
FCF growth 1Y-151.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-148.9%
OCF growth 3YN/A
OCF growth 5YN/A
ARCTURUS THERAPEUTICS HOLDIN / ARCT FAQ
Can you provide the ChartMill fundamental rating for ARCTURUS THERAPEUTICS HOLDIN?
ChartMill assigns a fundamental rating of 4 / 10 to ARCT.
What is the valuation status of ARCTURUS THERAPEUTICS HOLDIN (ARCT) stock?
ChartMill assigns a valuation rating of 0 / 10 to ARCTURUS THERAPEUTICS HOLDIN (ARCT). This can be considered as Overvalued.
What is the profitability of ARCT stock?
ARCTURUS THERAPEUTICS HOLDIN (ARCT) has a profitability rating of 1 / 10.
How financially healthy is ARCTURUS THERAPEUTICS HOLDIN?
The financial health rating of ARCTURUS THERAPEUTICS HOLDIN (ARCT) is 7 / 10.